InflaRx NV (FRA:IF0)
€ 1.35 0 (0%) Market Cap: 85.25 Mil Enterprise Value: 2.44 Mil PE Ratio: 0 PB Ratio: 0.89 GF Score: 32/100

InflaRx NV Corporate Call Transcript

Sep 11, 2023 / 12:30PM GMT
Release Date Price: €3.8 (+2.29%)
Laurie Doyle
MC Services AG - Moderator

Ladies and gentlemen, thank you for standing by. Welcome and thank you for joining InflaRx's conference call to discuss the results announced today from the Phase 1 study with INF904. (Conference Instructions)

I would now like to turn the call over to Dr. Niels Riedemann, CEO and Founder of InflaRx. Niels, please go ahead.

Niels Riedemann
InflaRx N.V. - CEO and Founder

Yes. Thank you so much, Laurie. Good morning, everyone on this call. It's our great pleasure to present to you today the results from our single ascending dose Phase 1 study of our new oral C5a receptor inhibitor. Before going into it, I would like to direct your attention on the next two slides briefly to our corporate disclaimers. We will be making forward-looking statement and also, I have some comparison to published data from other drugs. So please take note of the disclaimer. And then I would like to come to the next slide, please. One more.

Thank you. So with me today are representing InflaRx. I have our C-suite team. It's my

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot